NovaBiotics to present new data on their novel Cystic Fibrosis drugs at the European CF Society’s Annual Conference

Ecfs Logo Dark Blue Transparent 100H 0

NovaBiotics will present new efficacy data for their Lynovex® Cystic Fibrosis (CF) drug candidates at the European CF Society Conference (ECFS) in Liverpool, UK, June 5th-8th.

ECFS is a major international event and provides a forum for all with a common interest in CF to meet and discuss their latest findings. The NovaBiotics team will engage with their partners, collaborators and colleagues from the commercial, clinical and academic sectors of the CF community over the course of the conference.

Oral Lynovex is a late stage adjunct therapy for the treatment of pulmonary exacerbations of CF-associated lung disease. New data to be presented at ECFS demonstrates how the drug is highly effective in tackling antibiotic-resistant bacteria associated with exacerbations. The anti-virulence properties of Lynovex now elucidated further support previous preclinical and clinical data including the results from NovaBiotics’ CARE CF 1 study which concluded in 2018. NovaBiotics will also be presenting data on the potent and unique mucolytic mechanism of Lynovex in both oral form for exacerbations and inhaled form for maintenance of lung function in stable CF patients. Oral Lynovex is now ready to enter final, global registration clinical trials and inhaled Lynovex will be clinical testing-ready in the second half of 2019.

Dr Deborah O’Neil, CEO of NovaBiotics, said: “We are excited about the new data being presented at the ECFS annual conference. Our latest findings support what we have seen in clinical trials and in earlier laboratory tests and come at an exciting time as we gear up to clinical trials for the inhaled form of Lynovex and we are ready to enter final registration studies for oral Lynovex, which is the only exacerbation-specific intervention in development for CF.

“The data that will be presented in our talk on the recently concluded CARE CF 1 trial reiterates what I believe is such an important aspect of Lynovex in both oral and inhaled form; that it is not a mutation-specific treatment. We believe Lynovex, in oral and inhaled form, is part of a future standard-of-care therapy paradigm and can boost the impact of modulator therapies by mitigating otherwise inevitable exacerbation-driven lung function decline and reducing symptomology in stable disease.”

NovaBiotics, the Aberdeen-based clinical-stage biotechnology company, will be making a number of presentations at ECFS with Dr Douglas Fraser-Pitt, Principal Scientist at NovaBiotics and Professor Daniel Peckham, Leeds Hospital and University of Leeds, UK.

The details of the posters are as follows:

Title: Cysteamine has wide-ranging anti-virulence properties against cystic fibrosis pathogens

Poster number: P111

Presenter: Dr Douglas Fraser-Pitt

Date: Thursday 6 June 2019

Location: Poster Area on Lower Level

Time: 14.00-15.00

Title: Cysteamine impairs lipoic acid cofactor-mediated aspects of bacterial metabolism in CF pathogens

Poster number: P114

Presenter: Dr Douglas Fraser-Pitt

Date: Thursday 6 June 2019

Location: Poster Area on Lower Level

Time: 14.00–15.00

The details of the workshop are as follows:

Title: Evaluating appropriate PROMs in CARE-CF-1 trial: Lynovex®(cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacerbations

Workshop number: WS12.6

Presenter: Professor Daniel Peckham, Leeds

Date: Friday 7 June 2019

Location: Hall 1A

Time: 15.00 – 16.30

– Ends –

About NovaBiotics

NovaBiotics Ltd (NovaBiotics) is a leading clinical-stage biotechnology company focused on the design and development of first-in-class therapies for difficult-to-treat, medically unmet infectious diseases caused by bacteria and fungi and respiratory conditions including cystic fibrosis. A leading innovator in the anti-infectives space, the Company’s robust technology and business model has been validated through successful development, from concept to clinic, of a number of its product candidates. NovaBiotics also has a successful track record in securing significant funding and the most appropriate commercial collaborations to enable the delivery of the company’s high value medicinal candidates to markets of significant worth.

For further information please contact:

ABZ Mediacraft:

Erikka Askeland – Director

0044 (0)1224 360456

erikka@mediacraft.co.uk

NovaBiotics:

Dr Deborah O’Neil - CEO & CSO

0044 (0)1224 711377

deborah@novabiotics.co.uk